Showing results (221-230 of 369) with videos related to
Sort By:
Pageof 37
Cancer Cell|July 23, 2019
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune SuppressionWenjing Su, Hyun Ho Han, Yan Wang, et al.The Lancet. Oncology|December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysisJulia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.The Journal of Clinical Investigation|January 26, 2013
β4 Integrin signaling induces expansion of prostate tumor progenitorsToshiaki Yoshioka, Javier Otero, Yu Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and PrednisoneDana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.Urology|December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting SummaryMartin R Hofmann, Maha Hussain, Scott M Dehm, et al.Vaccine|April 8, 2004
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsPolly D Gregor, Jedd D Wolchok, Cristina R Ferrone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2019
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate CancerDaniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, et al.Journal of Pharmacokinetics and Pharmacodynamics|July 7, 2012
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model buildingEric A Sherer, Mark E Sale, Bruce G Pollock, et al.Pageof 37